<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964782</url>
  </required_header>
  <id_info>
    <org_study_id>31171</org_study_id>
    <nct_id>NCT00964782</nct_id>
  </id_info>
  <brief_title>The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation</brief_title>
  <official_title>The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Miracle Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will test the hypothesis that a single dose of sildenafil can increase the exercise
      capacity of pediatric patients with a Fontan Circulation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An increase in exercise capacity for patients administered sildenafil</measure>
    <time_frame>From 1 to 6 months from the date of the baseline stress test</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fontan Circulation</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil dosage will be 0.5mg/kg (max 20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive a look-alike placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>oral suspension, 0.5mg/kg, taken once prior to exercise stress test</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patient will receive a look-alike placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Composition of the placebo will be Ora-sweet and Ora-plus (1:1 ratio).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6-17 years

          -  Male or female

          -  Possess Fontan Circulation

        Exclusion Criteria:

          -  Severe heart failure (New York Heart Ass. functional class IV)

          -  Evidence of Fontan pathway obstruction

          -  History of exercise-induced severe arrhythmias

          -  Pregnancy (known or suspected)

          -  Orthopedic limitations that prevent ambulation on a treadmill

          -  Use of nitroglycerin

          -  Herbal medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Devyani Chowdhury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Devyani Chowdhury, MD</last_name>
    <phone>717-531-6847</phone>
    <email>dchowdhury@hmc.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew S. Dean, MS</last_name>
    <phone>717-531-1847</phone>
    <email>mdean@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chowdhury</last_name>
      <email>dchowdhury@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Devyani Chowdhury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen E Cyran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew S. Dean, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Devyani Chowdhury/MD</name_title>
    <organization>Penn State Hershey Medical Center</organization>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>sildenafil</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>Patients with Fontan Circulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 6, 2018</submitted>
    <returned>May 3, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

